1450981-87-9
1450981-87-9 structure
- Name: Letolizumab
- Chemical Name: Letolizumab
- CAS Number: 1450981-87-9
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Inflammation/Immunology
- Create Date: 2023-04-20 17:42:58
- Modify Date: 2023-04-20 17:42:58
-
Letolizumab (BMS-986004) is a dimer antibody construction targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time[1][2][3].
| Name | Letolizumab |
|---|
| Description | Letolizumab (BMS-986004) is a dimer antibody construction targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
CD40L |
| In Vivo | Letolizumab 降低了恒河猴肾移植后的排斥反应和 CCR7-CD45RA+ CD4+ T 细胞终末分化，当与巴利昔单抗 (Basiliximab，HY-108852)、吗替麦考酚酯 (Mycophenolate mofetil，HY-B0199) 和类固醇联合使用时[2]。 Letolizumab 抑制 CD40L 三聚体和 CHO-CD40L 在人类 B 细胞 (IC50 值分别为 3.6 nM 和 1.3 nM) 或非人类灵长类 B 细胞 (IC50 值分别为 3.8 nM 和 7.3 nM) 中的活力[2]。 Letolizumab (2、10 和 20 mg/kg；静脉注射；一周一次持续 10 周) 延长了肾移植后的恒河猴的存活时间[2]。 Animal Model: Rhesus macaques after renal transplantation[2]. Dosage: 2, 10 and 20 mg/kg. Administration: Intravenous injection; once a week for 10 weeks. Result: Increased the survival time. |
| References |
| No Any Chemical & Physical Properties |